While checkpoint blockade therapy has proven useful in protecting CD8+ T cells from anergy and exhaustion, a third type of immune dysfunction that does not appear to be related to co‐inhibitory signaling is also frequently observed in melanoma patients and is characterized by incompletely differentiated CD8+ T cells that have proliferated but failed to acquire effector functions [7, 9, 13]. Here, CD8A is linked to melanoma.